Product Description
PHAD™-504 was designed as a synthetic structural analog of detoxified monophosphoryl lipid A (MPLA) derived from E. coli lipopolysaccharide (LPS). It is structurally similar to PHAD™, differing only in the length of a single fatty acid chain. As expected, the activity of PHAD™-504 is quite similar to that of PHAD™, making the two products interchangeable as adjuvants in vaccine or immunotherapy formulations.
Order Guidelines
1. Price & Stock Available on Request. Click to send email to: service@iright.com
2. Please DO NOT make payment before confirmation.
3. Minimum order value of $1,000 USD required.
Collaboration
Tony Tang
Email: Tony.Tang@iright.com
Mobile/WhatsApp/Wechat: +86-17717886924